Related references
Note: Only part of the references are listed.Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer
I. H. Park et al.
ANNALS OF ONCOLOGY (2009)
Extended survival in women with brain Metastases from HER2 overexpressing breast cancer
David N. Church et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Defining prognosis for women with breast cancer and CNS metastases by HER2 status
S. Dawood et al.
ANNALS OF ONCOLOGY (2008)
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Phase 2 Trial of Temozolomide Using Protracted Low-dose and Whole-brain Radiotherapy for Nonsmall Cell Lung Cancer and Breast Cancer Patients With Brain Metastases
Raffaele Addeo et al.
CANCER (2008)
Survival in patients with brain metastases from breast cancer
April F. Eichler et al.
CANCER (2008)
Results of the phase III ENRICH (RT-016) study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain Metastases from breast cancer
J. H. Suh et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results
M. Danova et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival
Michelle E. Melisko et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer:: the dark side of the moon?: A meta-analysis of the randomized trials
Emilio Bria et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) disposition and drug interactions
Joseph W. Polli et al.
DRUG METABOLISM AND DISPOSITION (2008)
Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (efaproxyn) plus whole-brain radiation therapy for brain Metastases
Charles Scott et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2007)
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
Rupert Bartsch et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: A nested-case-control study and a pooled meta-analysis
Debora Macis et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Capecitabine therapy of central nervous system metastases from breast cancer
Meltem Ekenel et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
Mary C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multidisciplinary management of brain Metastases
April F. Eichler et al.
ONCOLOGIST (2007)
Trastuzumab treatment and the risk of central nervous system (CNS) metastases
M. C. Pinder et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
HER-2 overexpressed breast cancer and brain metastases
M. Lichinitser et al.
BREAST (2007)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Therapeutic management of metastatic brain tumors
Gregory M. Richards et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer
Zsolt Gabos et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
Edgardo Rivera et al.
CANCER (2006)
Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption
Manabu Kinoshita et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force
R. Soffietti et al.
EUROPEAN JOURNAL OF NEUROLOGY (2006)
Systemic high-dose intravenous methotrexate for central nervous system metastases
AB Lassman et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
H. J. Stemmler et al.
BREAST (2006)
Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
T Yau et al.
ACTA ONCOLOGICA (2006)
Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status
John Souglakos et al.
BREAST CANCER RESEARCH (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment
E Shmueli et al.
EUROPEAN JOURNAL OF CANCER (2004)
The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma
R Lai et al.
CANCER (2004)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Central nervous system metastases in women after multimodality therapy for high risk breast cancer
LA Carey et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment
AM Gonzalez-Angulo et al.
CANCER (2004)
Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival
KD Miller et al.
ANNALS OF ONCOLOGY (2003)
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
JC Bendell et al.
CANCER (2003)
Immuno-viral therapy as a new approach for the treatment of brain tumors
M Toda
DRUG NEWS & PERSPECTIVES (2003)
Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma
LJ Schouten et al.
CANCER (2002)
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors - Report of the Quality Standards Subcommittee of the American Academy of Neurology
MJ Glantz et al.
NEUROLOGY (2000)